Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease

被引：24
|
作者：
Asberom, Theodros
Zhao, Zhiqiang
Bara, Thomas A.
Clader, John W.
Greenlee, William J.
Hyde, Lynn A.
Josien, Hubert B.
Li, Wei
McPhail, Andrew T.
Nomeir, Amin A.
Parker, Eric M.
Rajagopalan, Murali
Song, Lixin
Wong, Gwendolyn T.
Zhang, Lili
Zhang, Qi
Pissarnitski, Dmitri A.
机构：
[1] Schering Plough Res Inst, Dept Chem Res, Kenilworth, NJ 07033 USA
[2] Schering Plough Res Inst, Dept Cent Nervous Syst, Kenilworth, NJ 07033 USA
[3] Duke Univ, Dept Chem, Durham, NC 27708 USA
[4] Schering Plough Res Inst, Dept Drug Metab & Pharmacokinet, Kenilworth, NJ 07033 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 02期
关键词：
Alzheimer's disease; gamma-secretase inhibitors; Kulinkovich reaction;
D O I：
10.1016/j.bmcl.2006.10.011
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Attachment of the cyclopropylcarbamate group to the piperidine core of gamma-secretase inhibitors leads to a dramatic increase of their in vitro potency. Strategies for subsequent improvement of the in vivo pharmacokinetic profile of the series are discussed. Resulting compounds significantly reduce A beta levels in TgCRND8 mice after a single PO dosing at 30 mpk. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：511 / 516
页数：6
相关论文
共 50 条
  • [41] Concomitant Astroglial Atrophy and Astrogliosis in a Triple Transgenic Animal Model of Alzheimer's Disease
    Olabarria, Markel
    Noristani, Harun N.
    Verkhratsky, Alexei
    Rodriguez, Jose J.
    GLIA, 2010, 58 (07) : 831 - 838
  • [42] Characterization of Alzheimer's disease transgenic animal model by Aβ, Tau and neuroinflammation PET tracers
    Kong, Yanyan
    Guan, Yihui
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [43] γ-secretase modulation and its promise for Alzheimer's disease:: A rationale for drug discovery
    Beher, Dirk
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (01) : 34 - 37
  • [44] The efficacy of acetylcholinerase inhibitors in a animal model of Alzheimer disease
    Dong, HX
    Bertchume, A
    Goico, B
    Csernansky, CA
    Vallera, D
    Csernansky, JG
    NEUROBIOLOGY OF AGING, 2004, 25 : S243 - S243
  • [45] Pivotal trials for β-secretase inhibitors in Alzheimer's
    Sheridan, Cormac
    NATURE BIOTECHNOLOGY, 2015, 33 (02) : 115 - 116
  • [46] Pivotal trials for β-secretase inhibitors in Alzheimer's
    Cormac Sheridan
    Nature Biotechnology, 2015, 33 : 115 - 116
  • [47] The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease
    Li, Hongmei
    Qin, Jun
    Dhondi, Pawan
    Zhou, Wei
    Vicarel, Monica
    Bara, Thomas
    Cole, David
    Josien, Hubert
    Pissarnitski, Dmitri
    Zhu, Zhaoning
    Palani, Anandan
    Aslanian, Robert
    Clader, John
    Czarniecki, Michael
    Greenlee, William
    Cohen-Williams, Mary
    Hyde, Lynn
    Song, Lixin
    Zhang, Lili
    Chu, Inhou
    Huang, Xianhai
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (02) : 466 - 471
  • [48] Disease-Modifying Approach to the Treatment of Alzheimer’s DiseaseFrom α-Secretase Activators to γ-Secretase Inhibitors and Modulators
    Francesco Panza
    Vincenzo Solfrizzi
    Vincenza Frisardi
    Cristiano Capurso
    Alessia D’Introno
    Anna M. Colacicco
    Gianluigi Vendemiale
    Antonio Capurso
    Bruno P. Imbimbo
    Drugs & Aging, 2009, 26 : 537 - 555
  • [49] Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease
    Gijsen, Harrie J. M.
    Bischoff, Francois P.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 55 - 69
  • [50] Transgenic approaches to model Alzheimer's disease
    Sommer, B
    Sturchler-Pierrat, C
    Abramowski, D
    Wiederhold, KH
    Calhoun, M
    Jucker, M
    Kelly, P
    Staufenbiel, M
    REVIEWS IN THE NEUROSCIENCES, 2000, 11 (01) : 47 - 51
12345